Federal Register / Vol. 61, No. 130 / Friday, July 5, 1996 / Notices 35265

Manual of Federal Practice, 4th Ed.

Bankruptcy Law & Practice, 6th Ed.

Bankruptcy (Epstein, Nickels & White)

Corbin on Contracts

Insurance Law (Appleman)

Search & Seizure (Thomson)

Ballantine’s Law Dictionary

California ADR Practice Guide

California Civil Practice Handbook:

Choice Between State and Federal

Courts

California Civil Trialbook

California Litigation By the Numbers

Court Rules Companion

California Negligence & Settlement

California Products Liability Law &

Practice

California Digest

California Trial

California Tort Law

Modern California Discovery

Colorado Trial Handbook

Trial Handbook for Connecticut

Lawyers

Florida Criminal Practice & Procedure

Florida Evidence 2d

Illinois Jurisprudence

Indiana Appellate Handbook 2d

Kentucky Probate PSL

Kentucky Workers’ Compensation PSL

Louisiana Code of Evidence—Annotated

Louisiana Successions

Louisiana Workers’ Compensation

Massachusetts Corporations PSL

Massachusetts Domestic Relations PSL

Massachusetts Landlord-Tenant Law

Massachusetts Real Estate PSL

Michigan Criminal Law

Michigan Digest

Michigan Law & Practice

New Jersey Criminal Procedure

New York Wills and Trusts

New York Estate Administration

Ohio Family Law

Ohio Probate

Pennsylvania Law Encyclopedia

Modern Texas Discovery

Texas Civil Pre-Trial Procedure

Texas Trial and Appellate Practice

Washington Trial Handbook

Wisconsin Digest

Exhibit C

Definition of HHI and Calculations for

Nine Markets

‘‘HHI’’ means the HerfindahlHirschman Index, a commonly accepted

measure of market concentration. It is

calculated by squaring the market share

of each firm competing in the market

and then summing the resulting

numbers. For example, for a market

consisting of four firms with shares of

thirty, thirty, twenty, and twenty

percent, the HHI is 2600

(302+302+202+202=2600). The HHI takes

into account the relative size and

distribution of the firms in a market and

approaches zero when a market consists

of a large number of firms of relatively

equal size. The HHI increases both as

the number of firms in the market

decreases and as the disparity in size

between those firms increases.

Markets in which HHI is between

1000 and 1800 are considered to be

moderately concentrated, and those in

which the HHI is in excess of 1800

points are considered to be

concentrated. Transactions that increase

the HHI by more than 100 points in

concentrated markets presumptively

raise antitrust concerns under the

Merger Guidelines. See Merger

Guidelines § 1.51.

The HHIs for the nine primary law

markets are as follows:

Post

merger

HHI

increase

The market for:

Enhanced United States

Supreme Court case law 5023 959

Enhanced United States

statutory law ................... 9019 3964

Enhanced California statutory law ........................... 8088 3866

Enhanced California case

law .................................. 4762 1540

Enhanced New York statutory law ........................... 8686 3792

Enhanced Massachusetts

statutory law ................... 8954 4234

Enhanced Michigan statutory law ........................... 8702 4196

Enhanced Washington

case law .......................... 4521 996

Enhanced Wisconsin case

law .................................. 5535 2424

Certificate of Service

I, Keith S. Blair, hereby certify that on

June 25, 1996, I caused a copy of the

Competitive Impact Statement, filed this

day in United States v. The Thomson

Corporation and West Publishing

Company, to be served on defendants

the Thomson Corporation and West

Publishing Company by having a copy

mailed, first class, postage prepaid, to:

Wayne D. Collins, Esq., Shearman &

Sterling, Citicorp Building, 153 East

53rd Street, New York, New York

10022, Counsel for The Thomson

Corporation.

James E. Schatz, Esq., Schatz Paquin

Lockridge Grindal & Holstein P.L.L.P.,

Suite 2200, 100 Washington Avenue

So., Minneapolis, MN 55401, Counsel

for West Publishing Company.

Dated: June 25, 1996,

Keith S. Blair.

[FR Doc. 96–16891 Filed 7–3–96; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

Manfacturer of Controlled Substances;

Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on May 13, 1996,

Dupont Pharmaceuticals, The Dupont

Merck Pharmaceutical Company, 1000

Stewart Avenue, Garden City, New York

11530, made application to the Drug

Enforcement Administration (DEA) for

registration as bulk manufacturer of the

basic classes of controlled substances

listed below:

Drug Schedule

Oxycodone (9143) ............................ II

Hydrocodone (9193) ......................... II

Oxymorphone (9652) ........................ II

The firm plans to manufacture the

listed controlled substances to make

finished products.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 3, 1996.

Dated: June 27, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–17063 Filed 7–3–96; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with

§ 1311.42 of Title 21, Code of Federal

Regulations (CFR), notice is hereby